ARTICLE | Clinical News
Celgosivir: Interim Phase II data
December 10, 2007 8:00 AM UTC
Interim 4-week data from a Phase II trial in 10 treatment-naïve patients showed that the median reduction in HCV RNA at 4 weeks was 3.5 log10 for celgosivir plus peginterferon alfa-2b and ribavirin vs...